By Inti Landauro
PARIS--The U.S. Food and Drug Administration has given its
approval to Sanofi SA's (SAN.FR) Cerdelga capsule for Gaucher
disease, the French pharmaceutical company said.
Gaucher disease is a genetic condition affecting the liver,
spleen, kidneys, lungs, brain and bone marrow.
"Cerdelga is expected to be available to patients within a
month," Sanofi said in a statement late Tuesday.
Sanofi's Genzyme unit has been working on an oral form of the
drug for 15 years, the statement said. Genzyme was the first with a
treatment for Gaucher disease 20 years ago.
Marketing applications for Cerdelga are being considered by the
European Medicines Agency and other authorities, the statement
said.
Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires